Seroatlas · Human Serome Atlas

GRIN1

Glutamate receptor ionotropic, NMDA 1

Also known as: GluN1, NMDAR1, NMDZ1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q05586
Gene
GRIN1
Ensembl
ENSG00000176884
Chromosome
9
Canonical length
938 aa
Protein class
Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters

OverviewNCBI Gene

The protein encoded by this gene is a critical subunit of N-methyl-D-aspartate receptors, members of the glutamate receptor channel superfamily which are heteromeric protein complexes with multiple subunits arranged to form a ligand-gated ion channel. These subunits play a key role in the plasticity of synapses, which is believed to underlie memory and learning. Cell-specific factors are thought to control expression of different isoforms, possibly contributing to the functional diversity of the subunits. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

938 residues, UniProt reviewed canonical sequence.

>Q05586|GRIN1
     1  MSTMRLLTLA LLFSCSVARA ACDPKIVNIG AVLSTRKHEQ MFREAVNQAN KRHGSWKIQL
    61  NATSVTHKPN AIQMALSVCE DLISSQVYAI LVSHPPTPND HFTPTPVSYT AGFYRIPVLG
   121  LTTRMSIYSD KSIHLSFLRT VPPYSHQSSV WFEMMRVYSW NHIILLVSDD HEGRAAQKRL
   181  ETLLEERESK AEKVLQFDPG TKNVTALLME AKELEARVII LSASEDDAAT VYRAAAMLNM
   241  TGSGYVWLVG EREISGNALR YAPDGILGLQ LINGKNESAH ISDAVGVVAQ AVHELLEKEN
   301  ITDPPRGCVG NTNIWKTGPL FKRVLMSSKY ADGVTGRVEF NEDGDRKFAN YSIMNLQNRK
   361  LVQVGIYNGT HVIPNDRKII WPGGETEKPR GYQMSTRLKI VTIHQEPFVY VKPTLSDGTC
   421  KEEFTVNGDP VKKVICTGPN DTSPGSPRHT VPQCCYGFCI DLLIKLARTM NFTYEVHLVA
   481  DGKFGTQERV NNSNKKEWNG MMGELLSGQA DMIVAPLTIN NERAQYIEFS KPFKYQGLTI
   541  LVKKEIPRST LDSFMQPFQS TLWLLVGLSV HVVAVMLYLL DRFSPFGRFK VNSEEEEEDA
   601  LTLSSAMWFS WGVLLNSGIG EGAPRSFSAR ILGMVWAGFA MIIVASYTAN LAAFLVLDRP
   661  EERITGINDP RLRNPSDKFI YATVKQSSVD IYFRRQVELS TMYRHMEKHN YESAAEAIQA
   721  VRDNKLHAFI WDSAVLEFEA SQKCDLVTTG ELFFRSGFGI GMRKDSPWKQ NVSLSILKSH
   781  ENGFMEDLDK TWVRYQECDS RSNAPATLTF ENMAGVFMLV AGGIVAGIFL IFIEIAYKRH
   841  KDARRKQMQL AFAAVNVWRK NLQDRKSGRA EPDPKKKATF RAITSTLASS FKRRRSSKDT
   901  STGGGRGALQ NQKDTVLPRR AIEREEGQLQ LCSRHRES

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against GRIN1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
3
Mean surface accessibility (rSASA)
0.33
Highest tissue expression
215 nTPM

Expression across tissuesHPA

Tissue

  • cerebral cortex: 215 nTPM
  • basal ganglia: 137 nTPM
  • hippocampal formation: 111 nTPM
  • cerebellum: 109 nTPM
  • hypothalamus: 93 nTPM
  • amygdala: 85 nTPM

Single-cell type

  • brain inhibitory neurons: 260 nCPM
  • brain excitatory neurons: 182 nCPM
  • retinal amacrine cells: 129 nCPM
  • other brain neurons: 119 nCPM
  • retinal ganglion cells: 89 nCPM
  • oligodendrocytes: 21 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • cerebral cortex: 748 nTPM
  • white matter: 423 nTPM
  • basal ganglia: 343 nTPM
  • hippocampal formation: 334 nTPM
  • amygdala: 304 nTPM
  • midbrain: 288 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about GRIN1.

Disease | AllUniProt

Conditions GRIN1 is implicated in, by any mechanism.

  • Neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal dominant (NDHMSD) MIM:614254
  • Neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal recessive (NDHMSR) MIM:617820
  • Developmental and epileptic encephalopathy 101 (DEE101) MIM:619814

Disease | GeneticClinVar

127 pathogenic / likely-pathogenic of 1,258 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Disease | ImmuneIEDB

Conditions an epitope on GRIN1 was assayed in.

Disease | AutoantibodyPubMed

Conditions in which antibodies against GRIN1 are reported. Each links to that disease's full target list.

Showing 20 of 48 — disease pages carrying at least 10 antigens.

ReferencesPubMed · IEDB

Publications for GRIN1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

586 publications

Show 20 more of 586 total

Reference: B cellIEDB

3 publications

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.31
gnomAD pLI
0.98
gnomAD missense Z
6.22
DepMap mean gene effect
-0.02
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of GRIN1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads GRIN1 as an antibody target. Whether an autoantibody or antibody against GRIN1 could matter depends on whether native GRIN1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

GRIN1 is annotated at the cell surface, where native GRIN1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label GRIN1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/GRIN1. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...